Filtered By:
Source: Clinical Cancer Research
This page shows you your search results in order of date. This is page number 5.
Order by Relevance | Date
Total 104 results found since Jan 2013.
Sorafenib inhibition of Mcl-1 accelerates ATRA induced apoptosis in differentiation responsive AML cells.
CONCLUSIONS: Inhibition of Mcl-1 is required for apoptosis induction in ATRA differentiation responsive AML cells. ATRA and Sorafenib can be developed as a novel drug combination therapy for AML patients because this drug combination augments apoptosis by inhibiting Bcl-2 and Mcl-1.
PMID: 26459180 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - October 12, 2015 Category: Cancer & Oncology Authors: Wang R, Xia L, Gabrilove JL, Waxman S, Jing Y Tags: Clin Cancer Res Source Type: research
Reversal of Warburg effect and reactivation of oxidative phosphorylation by differential inhibition of EGFR signaling pathways in non-small cell lung cancer.
CONCLUSIONS: Our findings indicate that EGFR inhibitors may reactivate oxidative phosphorylation of cancer cells and provide a mechanistic clue for the rational combination of agents targeting EGFR-dependent proliferation and glucose metabolism in cancer therapy.
PMID: 26216352 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - July 27, 2015 Category: Cancer & Oncology Authors: De Rosa V, Iommelli F, Monti M, Fonti R, Votta G, Stoppelli MP, Del Vecchio S Tags: Clin Cancer Res Source Type: research
siRNA lipid nanoparticle potently silence clusterin and delay progression when combined with androgen receptor co-targeting in enzalutamide resistant prostate cancer.
CONCLUSIONS: LNP siRNA can silence target genes in vivo and enable inhibition of traditionally non-druggable genes like CLU and other promising co-targeting approaches in ENZ-R CRPC therapeutics.
PMID: 26106075 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - June 23, 2015 Category: Cancer & Oncology Authors: Yamamoto Y, Lin PJ, Beraldi E, Zhang F, Kawai Y, Leong J, Katsumi H, Fazli L, Fraser R, Cullis PR, Gleave ME Tags: Clin Cancer Res Source Type: research
Modulation of glucocorticoid resistance in pediatric T-cell Acute Lymphoblastic Leukemia by increasing BIM expression with the PI3K/mTOR inhibitor BEZ235.
CONCLUSIONS: Our data support the further investigation of agents targeting the PI3K/mTOR pathway to modulate glucocorticoid resistance in T-ALL.
PMID: 26080839 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - June 16, 2015 Category: Cancer & Oncology Authors: Hall CP, Reynolds CP, Kang MH Tags: Clin Cancer Res Source Type: research
TLR9-Targeted STAT3 Silencing Abrogates Immunosuppressive Activity of Myeloid-Derived Suppressor Cells from Prostate Cancer Patients.
CONCLUSIONS: Overall, we demonstrate the accumulation of granulocytic MDSCs with prostate cancer progression and the feasibility of using TLR9-targeted STAT3siRNA delivery strategy to alleviate MDSC-mediated immunosuppression.
PMID: 25967142 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - May 12, 2015 Category: Cancer & Oncology Authors: Hossain DM, Pal SK, Moreira DF, Duttagupta P, Zhang Q, Won H, Jones JO, D'Apuzzo M, Forman SJ, Kortylewski M Tags: Clin Cancer Res Source Type: research
Highly expressed genes in rapidly proliferating tumor cells as new targets for colorectal cancer treatment.
CONCLUSION: We have characterized at the transcriptomic level the differences between colorectal cancer cells that vary in their growth rates, and identified novel candidate chemotherapeutic targets for the treatment of colorectal cancer.
PMID: 25944804 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - May 5, 2015 Category: Cancer & Oncology Authors: Bazzocco S, Andretta E, Rodrigues P, Garrido M, Alazzouzi H, Chionh F, Carton-Garcia F, Macaya I, Nieto R, Sanchez A, Schwartz S, Dopeso H, Bilic J, Mariadason JM, Arango D Tags: Clin Cancer Res Source Type: research
Regulator of chromosome condensation 2 identifies high-risk patients within both major phenotypes of colorectal cancer.
CONCLUSIONS: Impaired RCC2 affects functional and clinical endpoints of CRC. High-risk patients with either MSI or MSS tumors can be identified with cost-effective routine RCC2 assays.
PMID: 25910952 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - April 24, 2015 Category: Cancer & Oncology Authors: Bruun J, Kolberg M, Ahlquist TC, Royrvik E, Nome T, Leithe E, Lind GE, Merok MA, Rognum TO, Bjorkoy G, Johansen T, Lindblom A, Sun XF, Svindland A, Liestol K, Nesbakken A, Skotheim RI, Lothe RA Tags: Clin Cancer Res Source Type: research
Systematic screening identifies dual PI3K and mTOR inhibition as a conserved therapeutic vulnerability in osteosarcoma.
CONCLUSIONS: The approaches described here have identified dual inhibition of the PI3K/mTOR pathway as a sensitive, druggable target in OS and provide rationale for translational studies with these agents.
PMID: 25862761 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - April 10, 2015 Category: Cancer & Oncology Authors: Gupte A, Baker E, Wan SS, Stewart E, Loh A, Shelat AA, Gould CM, Chalk A, Taylor S, Lackovic K, Karlstrom A, Mutsaers A, Desai J, Madhamshettiwar PB, Zannettino AC, Burns C, Huang DC, Dyer M, Simpson KJ, Walkley C Tags: Clin Cancer Res Source Type: research
HDAC inhibition overcomes acute resistance to MEK inhibition in BRAF mutant colorectal cancer by down-regulation of c-FLIPL.
CONCLUSIONS: Our findings indicate that c-MET/STAT3-dependent upregulation of c-FLIPL expression is an important escape mechanism following MEKi treatment in BRAFMT CRC. Thus, combinations of MEKi with inhibitors of c-MET or c-FLIP (eg. HDAC inhibitors) could be potential novel treatment strategies for BRAFMT CRC.
PMID: 25813020 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - March 26, 2015 Category: Cancer & Oncology Authors: Carson R, Celtikci B, Fenning CS, Javadi A, Crawford N, Perez-Carbonell L, Lawler M, Longley DB, Johnston PG, Van Schaeybroeck S Tags: Clin Cancer Res Source Type: research
Antibody-mediated delivery of anti-KRAS-siRNA in vivo overcomes therapy resistance in colon cancer.
Conclusions:The coupling of siRNA against KRAS to anti-EGFR antibodies provides a novel therapy approach for KRAS-mutated EGFR-positive cancer cells in vitro and in vivo. These findings provide an innovative approach for cancer specific siRNA application and for enhanced therapeutic potential of monoclonal antibody therapy and personalized treatment of cancer entities.
PMID: 25589625 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - January 14, 2015 Category: Cancer & Oncology Authors: Baeumer S, Baeumer N, Appel N, Terheyden L, Fremerey J, Schelhaas S, Wardelmann E, Buchholz F, Berdel WE, Müller-Tidow C Tags: Clin Cancer Res Source Type: research
Low expression of the E3 Ubiquitin Ligase CBL Confers Chemoresistance in Human Pancreatic Cancer and is Targeted by Epidermal Growth Factor Receptor Inhibition.
Conclusions: Low CBL causes chemoresistance in PDAC via stress-induced EGFR activation that can be effectively abrogated by EGFR inhibition. These results suggest that dysregulation of ubiquitination is a key mechanism of EGFR hyperactivation in PDAC and that low CBL may define PDAC tumors likely to respond to erlotinib treatment.
PMID: 25348515 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - October 27, 2014 Category: Cancer & Oncology Authors: Kadera BE, Toste PA, Wu N, Li L, Nguyen AH, Dawson DW, Donahue TR Tags: Clin Cancer Res Source Type: research
Elevated serum angiopoietin-like protein 2 correlates with the metastatic properties of colorectal cancer: a serum biomarker for early diagnosis and recurrence.
Conclusions:Serum ANGPTL2 is a novel diagnostic and recurrence-predictive biomarker in patients with CRC.
PMID: 25294915 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - October 7, 2014 Category: Cancer & Oncology Authors: Toiyama Y, Tanaka K, Kitajima T, Shimura T, Kawamura M, Kawamoto A, Okugawa Y, Saigusa S, Hiro J, Inoue Y, Mohri Y, Goel A, Kusunoki M Tags: Clin Cancer Res Source Type: research
Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer.
Conclusions:Gemcitabine resistance in bladder cancer cell lines was associated with decreased dCK expression, but gemcitabine-resistant xenografts were responsive to combination low-dose gemcitabine/IR. We propose that dCK activity in tumour vasculature renders it gemcitabine-sensitive, which is sufficient to invoke a tumour response and permit tumour cell kill in gemcitabine-resistant tumours.
PMID: 25224279 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - September 15, 2014 Category: Cancer & Oncology Authors: Kerr M, Scott H, Groselj B, Stratford M, Karaszi K, Sharma N, Kiltie AE Tags: Clin Cancer Res Source Type: research
Identification of differentially expressed long non-coding RNAs in bladder cancer.
Conclusions: We report differentially expression profiles for numerous lncRNA in UC. We identify phenotype-specific expression and a potential mechanistic target to explain this observation. Further studies are required to validate lncRNAs as prognostic biomarkers in this disease.
PMID: 25165097 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - August 27, 2014 Category: Cancer & Oncology Authors: Peter S, Borkowska E, Drayton RM, Rakhit CP, Noon AP, Chen W, Catto JW Tags: Clin Cancer Res Source Type: research
Low PIAS3 expression in malignant mesothelioma is associated with increased STAT3 activation and poor patient survival.
Conclusion: These results suggest that PIAS3 protein expression impacts survival in mesothelioma patients and that PIAS3 activation could become a therapeutic strategy.
PMID: 25124686 [PubMed - as supplied by publisher]
Source: Clinical Cancer Research - August 14, 2014 Category: Cancer & Oncology Authors: Dabir S, Kluge A, Kresak AM, Yang M, Fu P, Groner B, Wildey G, Dowlati A Tags: Clin Cancer Res Source Type: research
